Sensitivity to change of AIMS2 and AIMS2-SF components in comparison to M-HAQ and VAS-pain

E Taal, J J Rasker, R P Riemsma

Objective: To examine sensitivity to change of Dutch versions of AIMS2 (arthritis impact measurement scales–2) and AIMS2-SF (short form) components, in comparison with M-HAQ (modified health assessment questionnaire) and the 100 mm visual analogue scale for pain (VAS-pain) in patients with rheumatoid arthritis.

Methods: 218 patients participated in a study on patient education. Participants completed the Dutch AIMS2, M-HAQ, and VAS-pain at baseline and after one year; 165 completed both assessments. The education programme did not have any effect on health status. Patients were classified according to change over one year in their responses to the AIMS2 question about general health perception: improved health (n = 32), no change (n = 101), and poorer health (n = 32). Changes in scores over one year were tested with paired t tests, and standardised response means were calculated for AIMS2 and AIMS2-SF components, M-HAQ total score, and VAS-pain in the three classifications of change in health perception.

Results: AIMS2 and AIMS2-SF physical, symptom, and affect components showed similar sensitivity to change. The physical and symptom components performed better than M-HAQ and VAS-pain. AIMS2 and AIMS2-SF social interaction and role components were not sensitive to changes in general health perception. The role component was only applicable in 63 patients, because the others were unemployed, disabled, or retired.

Conclusions: AIMS2-SF is a good alternative to the AIMS2 long form for the assessment of health status in rheumatoid arthritis, and is preferable to M-HAQ and VAS-pain. Use of the AIMS2-SF makes it easier and less costly to collect data and reduces the burden on patients.

The arthritis impact measurement scales–2 (AIMS2) is a reliable and valid self report questionnaire with 12 scales to assess five components of health status in patients with arthritis: physical, symptom (pain), affect, social interaction, and role components. Completion of the questionnaire is a burden for many patients because of its length (57 items). This length also limits its use in clinical research and in routine practice to monitor patients.

Guillemin et al developed a short form of the AIMS2 (AIMS2-SF). The number of items in the AIMS2-SF was reduced by 54%, from 57 to 26, and it assesses the same five components as the long form AIMS2. Studies on patients with rheumatoid arthritis in France and Norway showed AIMS2-SF to be as reliable, valid, sensitive to change as the AIMS2 long form. The AIMS2-SF was also shown to be a reliable and valid instrument among patients with osteoarthritis in the USA. We have constructed Dutch versions of the AIMS2 (both long and short form) and have shown these to be reliable and valid measures of health status among patients with rheumatoid arthritis. However, one important property of health status scales—responsiveness or sensitivity to change—has not been assessed in our studies with the Dutch short and long versions of the AIMS2.

Our aim in this study was to examine sensitivity to change in perceived health over a one year period for components of the Dutch versions of AIMS2 and AIMS2-SF among patients with rheumatoid arthritis. We also compared the sensitivity to change in the AIMS2 and AIMS2-SF physical and symptom components with other short measures of physical function (the modified health assessment questionnaire (M-HAQ)) and pain (the 100 mm visual analogue scale (VAS-pain)).

METHODS

Patients

Data were used from a study on patient education for patients with rheumatoid arthritis. All outpatients with this diagnosis (according to the 1987 American College of Rheumatology criteria) from the clinics of seven rheumatologists from two hospitals were asked by their rheumatologists to participate in a study on education for arthritis patients. Of 825 patients, 238 returned a form stating that they agreed to participate. These participants were then randomly assigned to three groups: group education with participation of a significant other (in most cases the spouse); group education for patients only; and a control group. A composite questionnaire was posted to each participating patient at baseline. In all, 218 respondents returned the questionnaires at baseline. Patients were asked to fill out questionnaires again immediately after the intervention, and after six and 12 months. For this study we used data from the baseline assessment and from the assessment after 12 months. For further details, see Riemsma et al.

Measures

AIMS2 and AIMS2-SF

All participants completed the Dutch AIMS2 questionnaire. All items in the Dutch AIMS2 are measured on five point Likert scales scored from 1 to 5. To obtain scale scores for the AIMS2 scales, the scores on the individual items in each scale were averaged. The AIMS2 consists of three subscales: physical, symptom and affect.

Abbreviations: AIMS2, arthritis impact measurement scales–2; AIMS2-SF, arthritis impact measurement scales–2, short form; M-HAQ, modified health assessment questionnaire; MPQ, McGill pain questionnaire; SF-36, short form 36-item general health questionnaire; SRM, standardised response mean; VAS, visual analogue scale
Table 1  Mean scores at baseline and mean changes at 12 months for AIMS2 long and short version component scores, VAS-pain, and M-HAQ

<table>
<thead>
<tr>
<th>Scale</th>
<th>Poorer health (n = 32)</th>
<th>No change (n = 101)</th>
<th>Improved health (n = 32)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical function</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIMS2 physical</td>
<td>2.16 (1.70)</td>
<td>-0.66 (1.16)**</td>
<td>-1.09 (0.23)</td>
</tr>
<tr>
<td>AIMS2-SF physical</td>
<td>2.33 (1.61)</td>
<td>-0.72 (1.31)**</td>
<td>-1.20 (0.23)</td>
</tr>
<tr>
<td>M-HAQ</td>
<td>1.57 (0.63)</td>
<td>-0.23 (0.40)**</td>
<td>-0.40 (0.01)</td>
</tr>
<tr>
<td><strong>Pain</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIMS2 symptom</td>
<td>4.74 (2.01)</td>
<td>-0.79 (1.54)**</td>
<td>-1.36 (0.22)</td>
</tr>
<tr>
<td>AIMS2-SF symptom</td>
<td>4.89 (2.19)</td>
<td>-0.94 (1.68)**</td>
<td>-1.65 (0.24)</td>
</tr>
<tr>
<td>VAS-pain</td>
<td>31.83 (21.11)</td>
<td>-8.73 (21.18)*</td>
<td>-17.39 (0.08)</td>
</tr>
<tr>
<td><strong>Affect</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIMS2 affect</td>
<td>2.75 (1.52)</td>
<td>-0.49 (1.72)</td>
<td>-1.12 (0.14)</td>
</tr>
<tr>
<td>AIMS2-SF affect</td>
<td>2.68 (1.48)</td>
<td>-0.48 (1.72)</td>
<td>-1.15 (0.12)</td>
</tr>
<tr>
<td><strong>Social</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIMS2 social</td>
<td>4.22 (1.60)</td>
<td>0.03 (0.16)</td>
<td>0.40 (0.45)</td>
</tr>
<tr>
<td>AIMS2-SF social</td>
<td>4.48 (1.29)</td>
<td>0.00 (0.00)</td>
<td>0.33 (0.00)</td>
</tr>
<tr>
<td><strong>Work</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIMS2 role</td>
<td>3.22 (2.92)</td>
<td>-1.49 (2.22)*</td>
<td>-2.83 (0.15)</td>
</tr>
<tr>
<td>AIMS2-SF role</td>
<td>2.79 (2.40)</td>
<td>-1.54 (3.19)</td>
<td>-3.47 (0.39)</td>
</tr>
</tbody>
</table>

Values are mean (SD). *p < 0.05; **p < 0.01; ***p < 0.001 tested with paired t-test.

AIMS2, arthritis impact measurement scales—2; AIMS2-SF, arthritis impact measurement scales—2, short form; M-HAQ, modified health assessment questionnaire; VAS, visual analogue scale.

RESULTS

The questionnaires were completed by 165 patients at baseline and at 12 months. The mean (SD) age of those at baseline and at 12 months was 56.6 (9.5) years (28 to 70), and the mean disease duration was 11.7 (9.8) years (range 0 to 53); 12.1% of patients was 56.6 (9.5) years (range 28 to 70), and the mean disease duration was 11.7 (9.8) years (range 0 to 53).

All analyses were carried out on the data from patients who completed the questionnaires at baseline and after 12 months. The mean (SD) age of those at baseline and at 12 months was 56.6 (9.5) years (28 to 70), and the mean disease duration was 11.7 (9.8) years (range 0 to 53).

All analyses were carried out on the data from patients who completed the questionnaires at baseline and after 12 months. The mean (SD) age of those at baseline and at 12 months was 56.6 (9.5) years (28 to 70), and the mean disease duration was 11.7 (9.8) years (range 0 to 53).
the patients had early rheumatoid arthritis (disease duration ≤ 2 years) and 60.6% of the patients were female.

Patients were classified into three groups based on changes over 12 months in general health perception: improved health (n = 32), no change (n = 101), and poorer health (n = 32).

In the “poorer health” group, scores on all three measures of physical function were worse after 12 months (p < 0.01), while in the “no change” group there were no significant changes in the scores (table 1). In the “improved health” group, scores improved (p < 0.001) on AIMS2 and AIMS2-SF physical components over 12 months, but scores on the M-HAQ after 12 months were not significantly different from baseline.

Scores on all three measures of pain were significantly worse after 12 months in the “poorer health” group (table 1). In the “improved health” group, scores on the two AIMS2 pain measures (symptom components) improved significantly over 12 months, but the VAS-pain scores did not change over this period. Patients who did not perceive their health to be changed after 12 months compared with baseline had no significant change in VAS-pain scores, but they had improved scores on the AIMS2 pain measures.

Affect scores for both versions of AIMS2 were worse in the “poorer health” group after 12 months, but the changes were not significant. Patients in the “no change” group had improved affect scores on AIMS2 but not on AIMS2-SF (p < 0.05). In the “improved health” group, affect scores on AIMS2 also improved significantly (p < 0.05), but not on AIMS2-SF.

There was no change in AIMS2 and AIMS2-SF social interaction scores in any of the three groups over 12 months.

The items of the role component were only applicable to 63 patients, because the other patients were unemployed, disabled, or retired. Only the AIMS2 role component scores in the “poorer health” group changed significantly over 12 months (p < 0.05).

SRMs for the AIMS2 short and long version component scores were very similar in all three groups (table 2). SRMs for M-HAQ and VAS-pain were smaller than the SRMs for the comparable AIMS2 physical and symptom components in the “poorer health” and “improved health” groups. In the “improved health” group, the SRMs for VAS-pain and M-HAQ were not significantly different from zero (95% confidence intervals include 0).

The AIMS2 long version affect component was more sensitive to changes in health perception than the short version; in the improved health group the SRM for the short version affect component was not significantly different from zero (the 95% confidence interval included 0).

Neither the short nor the long versions of the AIMS2 social interaction component were sensitive to changes in perceived health (table 2).

The AIMS2 long version of the role component was somewhat more sensitive to changes in perceived health than the short version, but the items of the role component were only applicable to 13 patients in the “poorer health” group and 11 in the “improved health” group.

**DISCUSSION**

This study shows that the long and short versions of the AIMS2 physical, symptom, and affect components are sensitive to changes in perceived health over one year. The SRMs for the short and long versions were very similar. The social component of both versions was not sensitive to changes in perceived health. However, AIMS2 social component scores for the patients did not differ much from healthy controls. It is not possible to draw conclusions about the sensitivity to change of the role components of either version because these were only applicable to 13 patients in the “poorer health” group and 11 patients in the “improved health” group.

The AIMS2 long form has been shown to be sensitive to change in studies in the USA, France, and Sweden. However, as in our study, the Swedish and French studies also showed that the AIMS2 social component has low sensitivity to change. The French and Norwegian versions of the AIMS2-SF had similar sensitivity to change as the long form AIMS2.
VAS-pain and M-HAQ proved less sensitive to change than the related AIMS2 short and long components; and neither VAS-pain nor M-HAQ were sensitive to improvements in perceived health over one year. The Norwegian AIMS2 long and short physical component was shown to have similar sensitivity to change as the M-HAQ and the physical function scale of the SF-36. However in other studies, the M-HAQ was found to lack sensitivity to change and to be worse at detecting treatment changes than the full HAQ.

The VAS-pain was less sensitive to deterioration of health status than AIMS2 short and long versions and SF-36, but had greater sensitivity to improvements in the Norwegian study. Bellamy et al compared the sensitivity to change of eight self rating pain scales in patients with rheumatoid arthritis. All scales proved capable of detecting improvement after four weeks of treatment with oxaprazin. VAS-pain and other simple pain scales (the five point Likert scale, numerical rating scales, continuous chromatic analogue scales) were more sensitive to change than more complex pain scales such as the MPQ (McGill pain questionnaire).

A limitation of our own and other studies with the AIMS2-SF is the use of data gathered with the long form of the AIMS2. This may cause a “framing” effect and lead to an overestimation of the similarity between the two forms. The psychometric properties of the AIMS2-SF should also be investigated with data gathered by the short form on its own.

In this study we used self reported changes in general health as an indicator of true change to analyse sensitivity to change. Havaardsholm et al used self reported change in global disease activity as an indicator of the sensitivity to change of the AIMS2 long and short versions. Others assessed sensitivity to change in AIMS2 short or long versions following treatment with, for example, methotrexate or DAB486IL-2 (a biological agent) which have proven clinical effects. On the one hand, the use of self reported change as an indicator limits the value of our results; both the AIMS2 and the perception of general health are self report measures, and it is to be expected that these scores are highly correlated. On the other hand, the use of self reported change in general health perception takes into account a general patients’ perspective. Sensitivity to change of the Dutch AIMS2 short and long forms for specific interventions such as treatment with methotrexate or infliximab remains to be proven.

Conclusions

Our study indicates that the AIMS2-SF is a good alternative to the AIMS2 long form for the assessment of health status in rheumatoid arthritis. Use of the AIMS2-SF instead of the long form makes it easier and less costly to collect data and reduces the burden on patients. M-HAQ and VAS-pain are also very short measures, but AIMS2-SF is preferable for the assessment of physical function and pain. M-HAQ and VAS-pain were less sensitive to change in perceived health than AIMS2-SF.

ACKNOWLEDGEMENTS

This study was supported by grants from the Dutch League against Rheumatism. We wish to thank all our respondents. We also gratefully acknowledge the cooperation of the rheumatologists Dr H J Bernelot Moens, Dr J J M Festen, Dr C J Haagisma, Dr M W M Kruijzen, Dr M A J van de Laar, and Dr J C M Oostveen.

REFERENCES

Sensitivity to change of AIMS2 and AIMS2-SF components in comparison to M-HAQ and VAS-pain

E Taal, J J Rasker and R P Riemsma

doi: 10.1136/ard.2003.014522

Updated information and services can be found at:
http://ard.bmj.com/content/63/12/1655

These include:

**References**
This article cites 16 articles, 5 of which you can access for free at:
http://ard.bmj.com/content/63/12/1655#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Immunology (including allergy) (5144)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)
- Pain (neurology) (883)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/